SFDA Adds Black Box Warnings On Levofloxacin/ Daiichi Sankyo's Cravit
This article was originally published in PharmAsia News
Executive Summary
In light of recent adverse drug reaction (ADR) monitoring results, China’s State FDA decided to amend oral and injectable levofloxacin (including hydrochloride, mesylate, and lactate) manuals